Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting

Indian Journal of Endocrinology and Metabolism
Manash P Baruah, Sanjay Kalra

Abstract

This study is aimed to evaluate the characteristics, treatment, and outcomes of patients treated with canagliflozin in the real-world setting within the first 4 months of the product's availability in India. It is a retrospective study with data collected from Indian clinical database. Patients aged 18 and above who were prescribed canagliflozin were included in this study. All the patients were on other antihyperglycemic agents (AHAs) before the initiation of canagliflozin. Overall, nine patients were included in the study, and data for these patients with mean duration of follow-up of 16 weeks was analyzed. Mean age was 47.9 years and mean duration of type 2 diabetes was 6.7 years. Among patients with available laboratory data at baseline and follow-up, mean glycosylated hemoglobin A1c (HbA1c) decreased from 9.0% at baseline to 6.8% at follow-up (P < 0.005); mean weight reduced from 69.9 kg at baseline to 67.9 kg at follow-up. When compared to baseline, the usage and or dose of other AHAs were reduced during follow-up. Canagliflozin after it became available in India, improved all glycemic parameters and also reduced the weight of the type two diabetic patients who were poorly controlled by multiple AHAs.

References

Aug 8, 2014·Diabetes Technology & Therapeutics·Ranjit UnnikrishnanViswanathan Mohan
Nov 27, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay Kalra

❮ Previous
Next ❯

Citations

Feb 2, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Awadhesh Kumar SinghViswanathan Mohan

❮ Previous
Next ❯

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.